Friday, August 22, 2014
Inquirer Daily News

Another diabetes drug in trouble?

The US Food and Drug Administration announced Friday it has begun a safety review of the diabetes drug Actos after preliminary results of an ongoing study showed the medication might increase the risk of bladder cancer in some patients.

Another diabetes drug in trouble?

The US Food and Drug Administration announced Friday it has begun a safety review of the diabetes drug Actos after preliminary results of an ongoing study showed the medication might increase the risk of bladder cancer in some patients.

Actos, also known as pioglitazone, is made by Takeda Pharmaceuticals. It has been in the news lately as the safer alternative to GlaxoSmithKline’s Avandia, or rosiglitazone, which has been linked to increased risk of heart failure, heart attacks and strokes.

The FDA announced the review after getting five-years of data from a 10-year observational study of Actos by Takeda. The results showed no overall increased risk of bladder cancer.

“However, there was an increased risk of bladder cancer in patients with the longest exposure to Actos and in those with the highest cumulative dose of the drug,” the FDA stated. “Patients should talk to their health care professional if they have concerns about Actos. They should not stop taking the drug unless told to do so by their health care professional.”

To check out more Check Up items go to www.philly.com/checkup.

About this blog

Check Up covers major health events in our region and offers everything from personal health advice to an expert look at health reform. Read about some of our bloggers here.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section

Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Latest Health Videos
Also on Philly.com:
Stay Connected